Oncolytic vaccinia virus mutants and using same for cancer treatment
US10842835B2 · kind B2 · utility
0Cited by
1References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 25, 2017 |
| Grant date | Nov 24, 2020 |
| Priority date | — |
| Expiry date | May 25, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/24132
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods utilizing vaccinia virus with mutations in E3L to infect and cause lysis of cancer cells with less than normal protein levels of RIP3 and/or DAI. Further, the disclosed vaccinia viruses with mutations in E3L cannot replicate well in cells with normal expression or upregulation of RIP3, DAI, and/or MLKL.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.